TCM
VRTX icon

Twin Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Twin Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$912K Sell
1,836
-43
-2% -$19.1K 0.1% 194
2026
Q1 		$839K Sell
1,879
-40
-2% -$18.7K 0.11% 184
2025
Q4 		$870K Buy
1,919
+14
+0.7% +$6.03K 0.11% 172
2025
Q3 		$746K Buy
+1,905
New +$796K 0.09% 192
2025
Q1 		– Sell
-2,933
Closed -$1.18M – 322
2024
Q4 		$1.18M Sell
2,933
-2,826
-49% -$1.31M 0.13% 154
2024
Q3 		$2.68M Sell
5,759
-135
-2% -$64.8K 0.3% 94
2024
Q2 		$2.76M Buy
5,894
+30
+0.5% +$13K 0.33% 81
2024
Q1 		$2.45M Sell
5,864
-328
-5% -$139K 0.3% 99
2023
Q4 		$2.52M Sell
6,192
-162
-3% -$59.8K 0.33% 92
2023
Q3 		$2.21M Sell
6,354
-441
-6% -$154K 0.32% 93
2023
Q2 		$2.39M Sell
6,795
-262
-4% -$88.3K 0.31% 96
2023
Q1 		$2.22M Sell
7,057
-3,564
-34% -$1.07M 0.3% 103
2022
Q4 		$3.07M Sell
10,621
-33
-0.3% -$10.1K 0.4% 76
2022
Q3 		$3.08M Sell
10,654
-70
-0.7% -$20.1K 0.42% 66
2022
Q2 		$3.02M Buy
10,724
+4,235
+65% +$1.13M 0.39% 80
2022
Q1 		$1.69M Buy
6,489
+85
+1% +$20.2K 0.18% 151
2021
Q4 		$1.41M Buy
6,404
+1,229
+24% +$239K 0.14% 169
2021
Q3 		$939K Buy
+5,175
New +$1.01M 0.1% 203
2019
Q1 		– Sell
-11,770
Closed -$1.95M – 278
2018
Q4 		$1.95M Sell
11,770
-33,450
-74% -$5.8M 0.11% 207
2018
Q3 		$8.72M Buy
45,220
+1,450
+3% +$258K 0.4% 74
2018
Q2 		$7.44M Buy
43,770
+300
+0.7% +$46.5K 0.37% 89
2018
Q1 		$7.08M Buy
43,470
+24,720
+132% +$4.04M 0.37% 90
2017
Q4 		$2.81M Buy
+18,750
New +$2.78M 0.14% 191

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Twin Capital Management's VRTX Position: Q2 2026 in Review

Twin Capital Management reduced its Vertex Pharmaceuticals (VRTX) stake by 2.3% in Q2 2026, selling an estimated $19.1K and leaving 1,836 shares worth $912K. The position accounts for 0.1% of the portfolio, ranked #194.

Twin Capital Management first reported a position in VRTX in Q4 2017 and has held it in 23 quarters since. The position peaked at $8.72M in Q3 2018. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Twin Capital Management held 1,836 shares of Vertex Pharmaceuticals worth $912K as of Q2 2026.
  • Twin Capital Management sold 43 Vertex Pharmaceuticals shares in Q2 2026, an estimated $19.1K.
  • Vertex Pharmaceuticals made up 0.1% of Twin Capital Management's portfolio in Q2 2026, its #194 holding.
  • Twin Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2017 and has held it in 23 quarters since.
  • Twin Capital Management's Vertex Pharmaceuticals position peaked at $8.72M in Q3 2018.
  • 1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Twin Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.